Department of Longevity and Biofunctional Medicine, Pusan National University School of Korean Medicine, Yangsan 50612, Republic of Korea.
Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Nutrients. 2024 Oct 17;16(20):3521. doi: 10.3390/nu16203521.
(1) Background: IBD (inflammatory bowel disease) is characterized by chronic intestinal inflammation leading to persistent symptoms and a lack of effective treatments. ZP () has been used in traditional Chinese medicine for its anti-inflammatory and antioxidant properties for the management of intestinal disorders. (2) Methods: This study aimed to investigate the components of ZP, their specific targets, and associated diseases using the TCMSP (Traditional Chinese Medicine Systems Pharmacology) analysis platform, TCMBank database, and ETCM2.0 (Encyclopedia of Traditional Chinese Medicine 2.0) database. Additionally, we explored the protective effects of ZP on the colon and the underlying molecular mechanisms in the treatment of IBD. (3) Results: We identified 59 compounds in ZP that target 38 genes related to IBD, including PTGS2, PPARG, and GPBAR1. In a mice model of DSS (dextran sodium sulfate)-induced colitis, ZP significantly reduced colonic epithelial damage and oxidative stress markers, such as iNOS and nitrotyrosine, demonstrating its antioxidant properties. (4) Conclusions: These findings suggest that ZP has protective effects against DSS-induced colonic damage owing to its anti-inflammatory and antioxidant properties, making it a potential candidate for IBD treatment. However, further research and clinical trials are required to confirm its therapeutic potential and safety in humans.
(1) 背景:炎症性肠病(IBD)的特征是慢性肠道炎症导致持续症状和缺乏有效治疗方法。ZP(紫珠)在传统中药中因其抗炎和抗氧化特性而被用于治疗肠道疾病。(2) 方法:本研究旨在使用 TCMSP(中药系统药理学)分析平台、TCMBank 数据库和 ETCM2.0(中药 2.0 百科全书)数据库,研究 ZP 的成分、其特定靶点以及与相关疾病的关系。此外,我们还探讨了 ZP 对结肠的保护作用及其在治疗 IBD 中的潜在分子机制。(3) 结果:我们在 ZP 中鉴定出 59 种化合物,这些化合物靶向与 IBD 相关的 38 个基因,包括 PTGS2、PPARG 和 GPBAR1。在 DSS(葡聚糖硫酸钠)诱导的结肠炎小鼠模型中,ZP 显著减轻结肠上皮损伤和氧化应激标志物,如 iNOS 和硝基酪氨酸,表明其具有抗氧化特性。(4) 结论:这些发现表明,ZP 具有抗炎和抗氧化特性,对 DSS 诱导的结肠损伤具有保护作用,使其成为治疗 IBD 的潜在候选药物。然而,需要进一步的研究和临床试验来确认其在人类中的治疗潜力和安全性。